BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The Day In Review: Dynavax Technologies Corporation (DVAX) Climbs On Journal Article


10/5/2006 4:58:40 PM

October 5, 2006 -- Dynavax rose 55% after positive trial results of its anti-ragweed therapy, Tolamba, were published in a journal article; GlaxoSmithKline won FDA approval of its FluLaval vaccine; Merck and Schering-Plough reported their anti-cholesterol drug, Vytorin, can say it is more effective than Crestor; Prana will begin a Phase IIa trial of its Alzheimer’s drug; Alkermes licensed rights to opioid receptor compounds from Rensselaer; GTC received a $1.4 million grant to fund research of a drug for solid tumors and autoimmune diseases; the FDA approved the contraceptive Yaz from Schering for premenstrual dysphoric disorder; Dyax will discover compounds that bind to targets identified by Trubion; GenVec will receive up to $52 million over five years to develop an HIV vaccine; and Trimeris reported that Fuzeon, together with a Merck drug, reduced HIV levels to undetectable levels. The Centient Biotech 200™ gained 53 points to 3897.56, an increase of 1.39%, far outpacing the broad market. More details...


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES